vs
美国鹰（AEO）与拜玛林制药（BMRN）财务数据对比。点击上方公司名可切换其他公司
美国鹰的季度营收约是拜玛林制药的1.6倍（$1.4B vs $874.6M），美国鹰净利率更高（6.7% vs -5.3%，领先12.0%），拜玛林制药同比增速更快（17.0% vs 5.7%），拜玛林制药自由现金流更多（$58.9M vs $-2.5M），过去两年拜玛林制药的营收复合增速更高（16.1% vs 2.3%）
American Eagle Outfitters是美国知名服饰及配饰零售商，总部位于宾夕法尼亚州匹兹堡市南区工业园。品牌1977年由杰里·西尔弗曼与马克·西尔弗曼兄弟创立，最初为零售风险投资公司的子公司，旗下还运营西尔弗曼男装。1980年创始人向肖滕斯坦家族出售一半股权，1991年售罄剩余股份，目前旗下拥有Aerie、Unsubscribed等多个品牌。
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
AEO vs BMRN — 直观对比
营收规模更大
AEO
是对方的1.6倍
$874.6M
营收增速更快
BMRN
高出11.3%
5.7%
净利率更高
AEO
高出12.0%
-5.3%
自由现金流更多
BMRN
多$61.4M
$-2.5M
两年增速更快
BMRN
近两年复合增速
2.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $874.6M |
| 净利润 | $91.3M | $-46.6M |
| 毛利率 | 40.5% | 68.5% |
| 营业利润率 | 8.3% | -5.1% |
| 净利率 | 6.7% | -5.3% |
| 营收同比 | 5.7% | 17.0% |
| 净利润同比 | 14.2% | -137.3% |
| 每股收益（稀释后） | $0.53 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEOBMRN
| Q4 25 | $1.4B | $874.6M | ||
| Q3 25 | $1.3B | $776.1M | ||
| Q2 25 | $1.1B | $825.4M | ||
| Q1 25 | — | $745.1M | ||
| Q4 24 | $1.3B | $747.3M | ||
| Q3 24 | $1.3B | $745.7M | ||
| Q2 24 | $1.1B | $712.0M | ||
| Q1 24 | $1.7B | $648.8M |
净利润AEOBMRN
| Q4 25 | $91.3M | $-46.6M | ||
| Q3 25 | $77.6M | $-30.7M | ||
| Q2 25 | $-64.9M | $240.5M | ||
| Q1 25 | — | $185.7M | ||
| Q4 24 | $80.0M | $124.9M | ||
| Q3 24 | $77.3M | $106.1M | ||
| Q2 24 | $67.8M | $107.2M | ||
| Q1 24 | $6.3M | $88.7M |
毛利率AEOBMRN
| Q4 25 | 40.5% | 68.5% | ||
| Q3 25 | 38.9% | 82.0% | ||
| Q2 25 | 29.6% | 81.8% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | 40.9% | 81.8% | ||
| Q3 24 | 38.6% | 74.7% | ||
| Q2 24 | 40.6% | 81.7% | ||
| Q1 24 | 36.6% | 80.7% |
营业利润率AEOBMRN
| Q4 25 | 8.3% | -5.1% | ||
| Q3 25 | 8.0% | -6.0% | ||
| Q2 25 | -7.8% | 33.5% | ||
| Q1 25 | — | 30.0% | ||
| Q4 24 | 8.2% | 21.6% | ||
| Q3 24 | 7.8% | 15.3% | ||
| Q2 24 | 6.8% | 16.9% | ||
| Q1 24 | 0.6% | 13.6% |
净利率AEOBMRN
| Q4 25 | 6.7% | -5.3% | ||
| Q3 25 | 6.0% | -4.0% | ||
| Q2 25 | -6.0% | 29.1% | ||
| Q1 25 | — | 24.9% | ||
| Q4 24 | 6.2% | 16.7% | ||
| Q3 24 | 6.0% | 14.2% | ||
| Q2 24 | 5.9% | 15.1% | ||
| Q1 24 | 0.4% | 13.7% |
每股收益（稀释后）AEOBMRN
| Q4 25 | $0.53 | $-0.22 | ||
| Q3 25 | $0.45 | $-0.16 | ||
| Q2 25 | $-0.36 | $1.23 | ||
| Q1 25 | — | $0.95 | ||
| Q4 24 | $0.41 | $0.65 | ||
| Q3 24 | $0.39 | $0.55 | ||
| Q2 24 | $0.34 | $0.55 | ||
| Q1 24 | $0.03 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $112.8M | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.6B | $6.1B |
| 总资产 | $4.2B | $7.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AEOBMRN
| Q4 25 | $112.8M | $1.3B | ||
| Q3 25 | $126.8M | $1.3B | ||
| Q2 25 | $87.9M | $1.2B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $160.2M | $942.8M | ||
| Q3 24 | $191.8M | $675.4M | ||
| Q2 24 | $300.5M | $972.1M | ||
| Q1 24 | $454.1M | $747.0M |
总债务AEOBMRN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
股东权益AEOBMRN
| Q4 25 | $1.6B | $6.1B | ||
| Q3 25 | $1.5B | $6.1B | ||
| Q2 25 | $1.5B | $6.0B | ||
| Q1 25 | — | $5.8B | ||
| Q4 24 | $1.7B | $5.7B | ||
| Q3 24 | $1.7B | $5.4B | ||
| Q2 24 | $1.8B | $5.3B | ||
| Q1 24 | $1.7B | $5.1B |
总资产AEOBMRN
| Q4 25 | $4.2B | $7.6B | ||
| Q3 25 | $4.1B | $7.6B | ||
| Q2 25 | $3.8B | $7.5B | ||
| Q1 25 | — | $7.1B | ||
| Q4 24 | $3.7B | $7.0B | ||
| Q3 24 | $3.5B | $6.9B | ||
| Q2 24 | $3.6B | $7.1B | ||
| Q1 24 | $3.6B | $6.9B |
负债/权益比AEOBMRN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.1M | $99.6M |
| 自由现金流经营现金流 - 资本支出 | $-2.5M | $58.9M |
| 自由现金流率自由现金流/营收 | -0.2% | 6.7% |
| 资本支出强度资本支出/营收 | 5.1% | 4.7% |
| 现金转化率经营现金流/净利润 | 0.74× | — |
| 过去12个月自由现金流最近4个季度 | $-169.8M | $725.0M |
8季度趋势，按日历期对齐
经营现金流AEOBMRN
| Q4 25 | $67.1M | $99.6M | ||
| Q3 25 | $27.8M | $368.7M | ||
| Q2 25 | $-54.7M | $185.3M | ||
| Q1 25 | — | $174.4M | ||
| Q4 24 | $52.9M | $185.6M | ||
| Q3 24 | $78.3M | $221.5M | ||
| Q2 24 | $-38.1M | $118.8M | ||
| Q1 24 | $296.4M | $47.0M |
自由现金流AEOBMRN
| Q4 25 | $-2.5M | $58.9M | ||
| Q3 25 | $-43.1M | $340.2M | ||
| Q2 25 | $-116.3M | $168.2M | ||
| Q1 25 | — | $157.6M | ||
| Q4 24 | $-7.8M | $166.1M | ||
| Q3 24 | $17.5M | $203.0M | ||
| Q2 24 | $-74.3M | $97.4M | ||
| Q1 24 | $256.8M | $20.9M |
自由现金流率AEOBMRN
| Q4 25 | -0.2% | 6.7% | ||
| Q3 25 | -3.4% | 43.8% | ||
| Q2 25 | -10.7% | 20.4% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | -0.6% | 22.2% | ||
| Q3 24 | 1.4% | 27.2% | ||
| Q2 24 | -6.5% | 13.7% | ||
| Q1 24 | 15.3% | 3.2% |
资本支出强度AEOBMRN
| Q4 25 | 5.1% | 4.7% | ||
| Q3 25 | 5.5% | 3.7% | ||
| Q2 25 | 5.7% | 2.1% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 4.7% | 2.6% | ||
| Q3 24 | 4.7% | 2.5% | ||
| Q2 24 | 3.2% | 3.0% | ||
| Q1 24 | 2.4% | 4.0% |
现金转化率AEOBMRN
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.94× | ||
| Q4 24 | 0.66× | 1.49× | ||
| Q3 24 | 1.01× | 2.09× | ||
| Q2 24 | -0.56× | 1.11× | ||
| Q1 24 | 46.93× | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEO
| American Eagle Brand | $800.4M | 59% |
| Aerie Brand | $429.1M | 31% |
| Other | $133.2M | 10% |
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
